Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

73%

8 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
5(45.5%)
Phase 4
3(27.3%)
Phase 1
2(18.2%)
Phase 2
1(9.1%)
11Total
Phase 3(5)
Phase 4(3)
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT07739589Phase 4Completed

A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

Role: lead

NCT06968481Phase 2Not Yet Recruiting

Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage

Role: lead

NCT04024163Phase 3Active Not Recruiting

Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease

Role: lead

NCT05303636Phase 4Active Not Recruiting

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

Role: lead

NCT05461573Phase 3Completed

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

Role: lead

NCT06282315Phase 3Recruiting

Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness

Role: lead

NCT03945513Phase 3Completed

A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles

Role: lead

NCT02392026Phase 4Completed

Safety and Tolerability of Metronidazole Gel 1.3%

Role: lead

NCT05993143Phase 3Terminated

Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50

Role: lead

NCT03739541Phase 1Completed

Benznidazole Absorption, Metabolism and Excretion Study

Role: collaborator

NCT03173742Phase 1Completed

Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)

Role: lead

All 11 trials loaded